UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors
  • Dec

    02

    UCB presents new data about the real-world experience of FINTEPLA® (fenfluramine) and rare epilepsy syndromes at 2023 American Epilepsy Society (AES) Annual Meeting

    Dec

    01

    UCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting

    Dec

    01

    Media Statement on levetiracetam (KEPPRA® and KEPPRA XR®) and DRESS